Lawrence Brandt, MD, professor of medicine and surgery at the Albert Einstein College of Medicine in New York City, discusses a study on the outcomes of fecal microbiota transplants on almost 100 patients across the country with refractory Clostridium difficile colitis. He explains that 91 percent of the patients experienced prompt relief. Including those who underwent a second transplant or a post-transplant course of medication, 98.3 percent of the patients experienced relief. This video was shot at the annual scientific conference of the American College of Gastroenterology.
He explains that Fecal Transplant has an extremely high success rate (90+ percent) in a very short period of time, with no known adverse effects and relatively low cost. Other conditions the procedure may be used to treat include irritable bowel disease, constipation, bloating, ulcerative colitis, Parkinson's disease, myoclonic dystrophy, autism, and morbid obesity. This video was shot at the annual scientific conference of the American College of Gastroenterology.